Publication: Population pharmacokinetics of artesunate and amodiaquine in African children
Issued Date
2009-09-21
Resource Type
ISSN
14752875
Other identifier(s)
2-s2.0-70349085389
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Malaria Journal. Vol.8, No.1 (2009)
Suggested Citation
Kasia Stepniewska, Walter Taylor, Sodiomon B. Sirima, Esperance B. Ouedraogo, Alphonse Ouedraogo, Adama Gansané, Julie A. Simpson, Caroline C. Morgan, Nicholas J. White, Jean René Kiechel Population pharmacokinetics of artesunate and amodiaquine in African children. Malaria Journal. Vol.8, No.1 (2009). doi:10.1186/1475-2875-8-200 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/27660
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Population pharmacokinetics of artesunate and amodiaquine in African children
Abstract
Background. Pharmacokinetic (PK) data on amodiaquine (AQ) and artesunate (AS) are limited in children, an important risk group for malaria. The aim of this study was to evaluate the PK properties of a newly developed and registered fixed dose combination (FDC) of artesunate and amodiaquine. Methods. A prospective population pharmacokinetic study of AS and AQ was conducted in children aged six months to five years. Participants were randomized to receive the new artesunate and amodiaquine FDC or the same drugs given in separate tablets. Children were divided into two groups of 70 (35 in each treatment arm) to evaluate the pharmacokinetic properties of AS and AQ, respectively. Population pharmacokinetic models for dihydroartemisinin (DHA) and desethylamodiaquine (DeAq), the principal pharmacologically active metabolites of AS and AQ, respectively, and total artemisinin anti-malarial activity, defined as the sum of the molar equivalent plasma concentrations of DHA and artesunate, were constructed using the non-linear mixed effects approach. Relative bioavailability between products was compared by estimating the ratios (and 95% CI) between the areas under the plasma concentration-time curves (AUC). Results. The two regimens had similar PK properties in young children with acute malaria. The ratio of loose formulation to fixed co-formulation AUCs, was estimated as 1.043 (95% CI: 0.956 to 1.138) for DeAq. For DHA and total anti-malarial activity AUCs were estimated to be the same. Artesunate was rapidly absorbed, hydrolysed to DHA, and eliminated. Plasma concentrations were significantly higher following the first dose, when patients were acutely ill, than after subsequent doses when patients were usually afebrile and clinically improved. Amodiaquine was converted rapidly to DeAq, which was then eliminated with an estimated median (range) elimination half-life of 9 (7 to 12) days. Efficacy was similar in the two treatments groups, with cure rates of 0.946 (95% CI: 0.840-0.982) in the AS+AQ group and 0.892 (95% CI: 0.787 - 0.947) in the AS/AQ group. Four out of five patients with PCR confirmed recrudescences received AQ doses < 10 mg/kg. Both regimens were well tolerated. No child developed severe, post treatment neutropaenia (<1,000/L). There was no evidence of AQ dose related hepatotoxicity, but one patient developed an asymptomatic rise in liver enzymes that was resolving by Day-28. Conclusion. The bioavailability of the co-formulated AS-AQ FDC was similar to that of the separate tablets for desethylamodiaquine, DHA and the total anti-malarial activity. These data support the use this new AS-AQ FDC in children with acute uncomplicated falciparum malaria. © 2009 Stepniewska et al; licensee BioMed Central Ltd.